论文部分内容阅读
目的:研究榄香烯注射液辅助VAD化疗的临床疗效及安全性。方法:选择在我院就诊的多发性骨髓瘤患者作为研究对象,随机分为给予榄香烯注射液辅助VAD化疗的观察组和VAD化疗的对照组,VCD化疗采用静脉注射长春新碱(0.4 mg)、阿霉素(9 mg)、口服地塞米松(40 mg),榄香烯注射液(0.4 g)静脉滴注。观察缓解情况、免疫功能及不良反应。结果:观察组的完全缓解率(38.46%)、部分缓解率(46.25%)以及CD3+(68.38±9.03)%,CD4+(47.18±8.49)%,CD4+/CD8+(2.17±0.42),自然杀伤细胞(NK)(9.31±1.34)%,肿瘤坏死因子-α(TNF-α)(1.53±0.21)ng·L-1,提高稳定率(92.31%)等高于对照组;CD8+(21.75±5.68)%以及头痛头晕(23.08%)、消化道症状(7.69%)、肾功能损害(7.69%)、肝功能损害(7.69%)、心功能损害(15.38%)、骨髓抑制(7.69%)均明显少于对照组。结论:榄香烯注射液辅助VAD化疗能够提高化疗缓解率、改善免疫功能、减少不良反应,具有积极的临床价值。
Objective: To study the clinical efficacy and safety of elemene injection in combination with VAD chemotherapy. Methods: Patients with multiple myeloma treated in our hospital were randomly divided into observation group receiving elemene injection assisted by VAD chemotherapy and control group receiving VAD chemotherapy. Vincristine (0.4 mg ), Doxorubicin (9 mg), dexamethasone (40 mg), and elemene (0.4 g). Observe the relief, immune function and adverse reactions. Results: The complete remission rate (38.46%), partial remission rate (46.25%), CD3 + (68.38 ± 9.03)%, CD4 (47.18 ± 8.49)%, CD4 + / CD8 + (2.17 ± 0.42) (9.31 ± 1.34)% and TNF-α (1.53 ± 0.21) ng · L-1, respectively, which was significantly higher than that of the control group (92.31% (23.08%), gastrointestinal symptoms (7.69%), renal dysfunction (7.69%), hepatic dysfunction (7.69%), cardiac dysfunction (15.38%) and myelosuppression Control group. Conclusion: Elemene injection assisted VAD chemotherapy can improve the response rate of chemotherapy, improve immune function and reduce adverse reactions, which has a positive clinical value.